In today's world, ACVR2B is a highly relevant issue that impacts society in different aspects. For decades, ACVR2B has been the object of study and interest by experts, researchers and professionals in different areas. Its influence ranges from economics to politics, including culture and the environment. In this article, we will explore in detail the different aspects related to ACVR2B, analyzing its importance, its implications and the possible future scenarios that its development may entail. From its origins to the present, ACVR2B has given rise to endless debates and reflections that have contributed to enriching knowledge about this phenomenon.
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.[7]
^De Winter JP, De Vries CJ, Van Achterberg TA, Ameerun RF, Feijen A, Sugino H, De Waele P, Huylebroeck D, Verschueren K, Van Den Eijden-Van Raaij AJ (May 1996). "Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors". Exp. Cell Res. 224 (2): 323–34. doi:10.1006/excr.1996.0142. PMID8612709.
De Winter JP, De Vries CJ, Van Achterberg TA, Ameerun RF, Feijen A, Sugino H, De Waele P, Huylebroeck D, Verschueren K, Van Den Eijden-Van Raaij AJ (1996). "Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors". Exp. Cell Res. 224 (2): 323–34. doi:10.1006/excr.1996.0142. PMID8612709.
McPherron AC, Lawler AM, Lee SJ (1999). "Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11". Nat. Genet. 22 (3): 260–4. doi:10.1038/10320. PMID10391213. S2CID1172738.
Bondestam J, Horelli-Kuitunen N, Hildén K, Ritvos O, Aaltonen J (1999). "Assignment of ACVR2 and ACVR2B the human activin receptor type II and IIB genes to chromosome bands 2q22.2-->q23.3 and 3p22 and the human follistatin gene (FST) to chromosome 5q11.2 by FISH". Cytogenet. Cell Genet. 87 (3–4): 219–20. doi:10.1159/000015429. PMID10702675. S2CID36135054.
Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC (2001). "Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE)". Mol. Cell. Endocrinol. 174 (1–2): 99–110. doi:10.1016/S0303-7207(00)00447-0. PMID11306176. S2CID10648768.
Schneider-Kolsky ME, Manuelpillai U, Waldron K, Dole A, Wallace EM (2002). "The distribution of activin and activin receptors in gestational tissues across human pregnancy and during labour". Placenta. 23 (4): 294–302. doi:10.1053/plac.2002.0787. PMID11969340.